SM-102

SM-102 is an ionizable cationic lipid (pKa = 6.68) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA and plasmid DNA in vitro and in vivo. It inhibits inward-rectifying potassium currents mediated by human-ether-a-go-go (hERG), also known as Kv11. in GH3 rat pituitary cells and MA-10 mouse Leydig cells (IC50s = 108 and 98 µM, respectively). Administration of luciferase mRNA in SM-102-containing LNPs induces hepatic luciferase expression in mice. LNPs containing SM-102 and Q1-SM-102 (Cay-41239) as a cationic lipid pair (CLP) and encapsulating a luciferase reporter induce luciferase expression in the lungs and spleen in mice. Intramuscular immunization of LNPs containing SM-102 and encapsulating mRNA encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein increases serum SARS-CoV-2 spike glycoprotein-specific IgG titers in mice. LNPs containing SM-102 and encapsulating mRNA encoding beta-catenin increase bone volume in a mouse model of tibia fracture repair when administered via injection to the fracture callus. Formulations containing SM-102 have been used in the development of LNPs for delivery of mRNA-based vaccines., , Read our statement on SM-102 for research use only. SM-102 is an ionizable cationic lipid (pKa = 6.68) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA and plasmid DNA in vitro and in vivo. It inhibits inward-rectifying potassium currents mediated by human-ether-a-go-go (hERG), also known as Kv11.1, in GH3 rat pituitary cells and MA-10 mouse Leydig cells (IC50s = 108 and 98 µM, respectively). Administration of luciferase mRNA in SM-102-containing LNPs induces hepatic luciferase expression in mice. LNPs containing SM-102 and Q1-SM-102 (Cay-41239) as a cationic lipid pair (CLP) and encapsulating a luciferase reporter induce luciferase expression in the lungs and spleen in mice. Intramuscular immunization of LNPs containing SM-102 and encapsulating mRNA encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein increases serum SARS-CoV-2 spike glycoprotein-specific IgG titers in mice. LNPs containing SM-102 and encapsulating mRNA encoding beta-catenin increase bone volume in a mouse model of tibia fracture repair when administered via injection to the fracture callus. Formulations containing SM-102 have been used in the development of LNPs for delivery of mRNA-based vaccines. Read our statement on SM-102 for research use only. SMILES: OCCN(CCCCCCCC(OC(CCCCCCCC)CCCCCCCC)=O)CCCCCC(OCCCCCCCCCCC)=O. InChi Code: InChI=1S/C44H87NO5/c1-4-7-10-13-16-17-18-24-32-41-49-43(47)35-29-25-31-38-45(39-40-46)37-30-23-19-22-28-36-44(48)50-42(33-26-20-14-11-8-5-2)34-27-21-15-12-9-6-3/h42,46H,4-41H2,1-3H3. InChi Key: BGNVBNJYBVCBJH-UHFFFAOYSA-N